FindTrial
Sign In

Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair

A Study of the Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01756560
Enrollment
2
Registered
2012-12-27
Start date
2013-01-31
Completion date
2015-01-31
Last updated
2019-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duration of Pain Relief

Keywords

anterior cruciate ligament, block duration

Brief summary

Anterior cruciate ligament reapair is a painful procedure. Single shot femoral and sciatic nerve block only last 12-16 hrs. Since dexamethasone prolongs brachial plexus block, using it in lower extremity blocks will prolong the analgesia to provide better outpatient pain relief after surgery at home.

Interventions

DRUGdexamethsone
DRUGBupivacaine

Sponsors

University of Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age 18-75, no contraindication to regional anesthesia

Exclusion criteria

* peripheral neuropathy

Design outcomes

Primary

MeasureTime frame
Analgesia Duration72 hours

Countries

United States

Participant flow

Participants by arm

ArmCount
Control
in this group, plain bupivacaine will be used to block femoral and sciatic nerve Bupivacaine
2
Dexamethasone
Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve dexamethsone Bupivacaine
0
Total2

Baseline characteristics

CharacteristicControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
2 Participants2 Participants
Region of Enrollment
United States
2 participants2 participants
Sex: Female, Male
Female
1 Participants1 Participants
Sex: Female, Male
Male
1 Participants1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 20 / 0
other
Total, other adverse events
0 / 20 / 0
serious
Total, serious adverse events
0 / 20 / 0

Outcome results

Primary

Analgesia Duration

Time frame: 72 hours

Population: study terminated early due to lack of resources to recruit subjects and no data was collected for Outcome measures

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026